BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 545 filers reported holding BIO-TECHNE CORP in Q1 2024. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,844,629 | -1.7% | 25,745 | -3.5% | 0.15% | +7.2% |
Q1 2024 | $1,877,301 | -1.8% | 26,670 | +7.6% | 0.14% | +4.5% |
Q4 2023 | $1,912,333 | +20.4% | 24,784 | +6.2% | 0.13% | -5.0% |
Q3 2023 | $1,587,937 | -13.0% | 23,328 | +4.3% | 0.14% | -9.7% |
Q2 2023 | $1,825,084 | +10.7% | 22,358 | +0.6% | 0.15% | +8.5% |
Q1 2023 | $1,648,650 | -10.0% | 22,222 | +0.6% | 0.14% | -2.1% |
Q4 2022 | $1,831,068 | +31.3% | 22,093 | +349.9% | 0.14% | -0.7% |
Q3 2022 | $1,395,000 | -19.3% | 4,911 | -1.5% | 0.15% | -15.6% |
Q2 2022 | $1,729,000 | -4.3% | 4,988 | +19.6% | 0.17% | +6.8% |
Q1 2022 | $1,806,000 | +10.4% | 4,170 | +31.9% | 0.16% | +11.7% |
Q4 2021 | $1,636,000 | +38.5% | 3,162 | +29.7% | 0.14% | +19.8% |
Q3 2021 | $1,181,000 | +18.0% | 2,437 | +9.6% | 0.12% | +21.0% |
Q2 2021 | $1,001,000 | +32.9% | 2,224 | +12.8% | 0.10% | +17.6% |
Q1 2021 | $753,000 | +39.4% | 1,972 | +15.9% | 0.08% | +25.0% |
Q4 2020 | $540,000 | +34.7% | 1,702 | +5.3% | 0.07% | +19.3% |
Q3 2020 | $401,000 | -6.1% | 1,617 | 0.0% | 0.06% | -8.1% |
Q2 2020 | $427,000 | +52.0% | 1,617 | +9.0% | 0.06% | +26.5% |
Q1 2020 | $281,000 | -9.6% | 1,483 | +4.6% | 0.05% | +11.4% |
Q4 2019 | $311,000 | -1.6% | 1,418 | -12.1% | 0.04% | -2.2% |
Q3 2019 | $316,000 | -4.5% | 1,614 | +1.7% | 0.04% | -6.2% |
Q2 2019 | $331,000 | +11.8% | 1,587 | +6.3% | 0.05% | 0.0% |
Q1 2019 | $296,000 | +39.6% | 1,493 | +1.9% | 0.05% | -69.0% |
Q4 2018 | $212,000 | – | 1,465 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |